AI-accelerated
Drug Discovery for
Precision Medicine

End-to-end drug discovery platform for precision medicine to provide dedicated drug discovery workflows tailored to challenging drug targets, indications and modalities.

Monospecific

Small molecules

Linear peptides

Cyclic peptides

Peptidomimetics

Bispecific

Internalisation and relocalization enhancers

Protein proximity engagers

Degraders (PROTACs/LYTACs)

Membranotropic conjugates

PPI modulators

Predicting PPI interfaces

PPI disruptors

PPI stabilisers

Molecular glues

Antibody mimetics

Addressing targets validated by antibodies

Highly permeable and selective

Oral administration

Optimised lipid-based formulations

End-to-end Drug Discovery for Precision Medicine

Our platform is tailored to the patient specific targets and allows designing highly selective and potent drug candidates with a high success rate

Target
Identification

Advanced identification of potential targets for precision medicine using best-in-class omics and population-level data analysis

Drug Candidate Design

40+ proprietary AI models are applied to design novel drugs for precision medicine using proprietary multi-level selectivity assessment

Experimental Feedback via Active Learning

Iterative experimental feedback integration from In vitro, in vivo and structure determination techniques to enforce target specificity.

End-to-end Drug Discovery
for Precision Medicine